- Report
- June 2025
- 193 Pages
Global
From €4573EUR$4,950USD£3,831GBP
- Report
- June 2025
- 300 Pages
Global
From €3338EUR$3,613USD£2,796GBP
€3927EUR$4,250USD£3,289GBP
- Report
- October 2024
- 83 Pages
Global
From €4158EUR$4,500USD£3,482GBP
- Report
- August 2024
- 41 Pages
Global
From €919EUR$995USD£770GBP
- Report
- January 2024
- 213 Pages
Global
From €4296EUR$4,650USD£3,598GBP
- Report
- September 2023
- 114 Pages
Global
From €2726EUR$2,950USD£2,283GBP
- Report
- September 2023
- 89 Pages
From €2726EUR$2,950USD£2,283GBP
- Report
- September 2023
- 107 Pages
Asia Pacific
From €3188EUR$3,450USD£2,670GBP
- Report
- September 2023
- 101 Pages
North America
From €2726EUR$2,950USD£2,283GBP
- Report
- September 2023
- 194 Pages
Global
From €4573EUR$4,950USD£3,831GBP
- Report
- August 2023
- 300 Pages
Latin America
From €4527EUR$4,900USD£3,792GBP
- Report
- August 2023
- 300 Pages
Asia Pacific
From €4527EUR$4,900USD£3,792GBP
- Report
- August 2023
- 300 Pages
Africa, Middle East
From €4527EUR$4,900USD£3,792GBP
- Report
- August 2023
- 1350 Pages
Global
From €8223EUR$8,900USD£6,887GBP
- Report
- August 2023
- 300 Pages
Europe
From €4527EUR$4,900USD£3,792GBP
- Report
- August 2023
- 51 Pages
India
From €554EUR$600USD£464GBP
- Report
- August 2023
- 51 Pages
Argentina
From €554EUR$600USD£464GBP
- Report
- August 2023
- 51 Pages
South Korea
From €554EUR$600USD£464GBP
- Report
- August 2023
- 51 Pages
South Africa
From €554EUR$600USD£464GBP
- Report
- August 2023
- 51 Pages
Australia
From €554EUR$600USD£464GBP

The Viral Vector market is a subset of the biotechnology industry that focuses on the development and production of viral vectors for gene therapy. Viral vectors are modified viruses that are used to deliver genetic material into cells, allowing for the expression of a desired gene. This technology has been used to treat a variety of diseases, including cancer, genetic disorders, and infectious diseases.
Viral vectors are produced through a variety of methods, including recombinant DNA technology, synthetic biology, and cell-based systems. The production of viral vectors requires specialized equipment and expertise, making it a highly specialized field.
The Viral Vector market is highly competitive, with a number of companies offering products and services. Some of the major players in the market include Novartis, Merck, Pfizer, AstraZeneca, and Sanofi. Additionally, there are a number of smaller companies that specialize in the production of viral vectors, such as Viralgen, Oxford BioMedica, and Vigene Biosciences. Show Less Read more